PA8782301A1 - Tratamiento de leucemia resistente al imatinte - Google Patents
Tratamiento de leucemia resistente al imatinteInfo
- Publication number
- PA8782301A1 PA8782301A1 PA20088782301A PA8782301A PA8782301A1 PA 8782301 A1 PA8782301 A1 PA 8782301A1 PA 20088782301 A PA20088782301 A PA 20088782301A PA 8782301 A PA8782301 A PA 8782301A PA 8782301 A1 PA8782301 A1 PA 8782301A1
- Authority
- PA
- Panama
- Prior art keywords
- impact resistant
- resistant leukemia
- leukemia treatment
- treatment
- quinolinacarbonitrilos
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93265007P | 2007-06-01 | 2007-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8782301A1 true PA8782301A1 (es) | 2009-01-23 |
Family
ID=39639071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20088782301A PA8782301A1 (es) | 2007-06-01 | 2008-05-30 | Tratamiento de leucemia resistente al imatinte |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11103497B2 (https=) |
| EP (4) | EP2152267A2 (https=) |
| JP (3) | JP5888853B2 (https=) |
| KR (1) | KR101493543B1 (https=) |
| CN (1) | CN101686973B (https=) |
| AU (1) | AU2008260070B9 (https=) |
| BR (1) | BRPI0812355A2 (https=) |
| CA (3) | CA2964162C (https=) |
| CL (1) | CL2008001577A1 (https=) |
| CY (2) | CY1115251T1 (https=) |
| DK (2) | DK2478905T3 (https=) |
| ES (2) | ES2881391T3 (https=) |
| HU (1) | HUE055524T2 (https=) |
| IL (1) | IL202407A0 (https=) |
| MX (1) | MX2009013069A (https=) |
| PA (1) | PA8782301A1 (https=) |
| PL (2) | PL2478905T3 (https=) |
| PT (2) | PT2478905E (https=) |
| RU (1) | RU2464026C2 (https=) |
| SI (2) | SI2478905T1 (https=) |
| TW (1) | TW200908982A (https=) |
| WO (1) | WO2008150957A2 (https=) |
| ZA (1) | ZA200908480B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964162C (en) | 2007-06-01 | 2019-12-31 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
| SG192769A1 (en) | 2011-03-04 | 2013-09-30 | Glaxosmithkline Ip No 2 Ltd | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| RU2662810C2 (ru) | 2013-02-21 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Хиназолины в качестве ингибиторов киназы |
| KR101733665B1 (ko) | 2015-05-06 | 2017-05-10 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 |
| JP2022544700A (ja) * | 2019-08-22 | 2022-10-20 | バイオヘイブン・セラピューティクス・リミテッド | 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子 |
| CN115944636A (zh) * | 2022-11-01 | 2023-04-11 | 华南师范大学 | 博舒替尼在抑制i-motif结构上的应用 |
| WO2025024311A2 (en) * | 2023-07-21 | 2025-01-30 | Icahn School Of Medicine At Mount Sinai | G9a/glp inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| AU2002245296B2 (en) * | 2001-01-25 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
| PT2017335E (pt) | 2001-10-05 | 2011-03-02 | Novartis Ag | Domínios da cinase abl mutados |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20050010780A1 (en) * | 2003-07-09 | 2005-01-13 | Kane John Richard | Method and apparatus for providing access to personal information |
| EP1680119A1 (en) * | 2003-11-06 | 2006-07-19 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| NL1031674C2 (nl) | 2005-04-25 | 2007-04-26 | Pfizer | Antilichamen tegen myostatine. |
| DE602006014540D1 (en) * | 2005-05-16 | 2010-07-08 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| EP1904654A2 (en) | 2005-07-15 | 2008-04-02 | Brystol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides |
| BRPI0616923A2 (pt) | 2005-10-06 | 2011-07-05 | Lilly Co Eli | anticorpos monoclonais, seus usos e composição farmacêutica |
| EP1948820A2 (en) * | 2005-11-04 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
| CA2964162C (en) | 2007-06-01 | 2019-12-31 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
-
2008
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en not_active Ceased
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active Active
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
-
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
-
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
-
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
-
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8782301A1 (es) | Tratamiento de leucemia resistente al imatinte | |
| BRPI0813966A8 (pt) | Usos de mdl-1 | |
| CY1118349T1 (el) | Παραγοντες συνδεσης me cd19 και χρησεις αυτων | |
| CL2008000822A1 (es) | Metodo para el tratamiento de la obesidad usando un inhibidor sglt2. | |
| CY1118523T1 (el) | Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus | |
| GT201400191A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| CY1119218T1 (el) | Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp) | |
| CR9301S (es) | Cuerpo de grifo | |
| CR20110492A (es) | Compuestos tetracíclicos | |
| MX2012013256A (es) | Composiciones y metodos para el tratamiento de leucemia. | |
| UY33756A (es) | Compuesto biciclico | |
| UY32730A (es) | Inhibidores de cyp17 | |
| MX2009005631A (es) | Sulfuro de zinc transparente que tiene alta area superficial especifica. | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| MX2010009003A (es) | Ciclohexanodimetanamina por aminacion directa de ciclohexanodimetanol. | |
| ECSP10010409A (es) | INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 | |
| PA8772701A1 (es) | "COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO)-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA" | |
| DOP2010000302A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| MX2010005114A (es) | Uso de las soluciones de aceite de menta o de l-carvona para el tratamiento fungicida y/o antigerminacion de bulbos y/o tuberculos. | |
| CR20110202A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| BR112012004902A2 (pt) | compostos de revestimentos flexível com preponderância de composição mineral | |
| SE0800742L (sv) | Vikttäcke | |
| MX2009009490A (es) | Profarmacos novedosos. | |
| CL2007000773A1 (es) | Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd. |